Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

Sallman, D A; Komrokji, R; Vaupel, C; Cluzeau, T; Geyer, S M; McGraw, K L; Al Ali, N H; Lancet, J; McGinniss, M J; Nahas, S; Smith, A E; Kulasekararaj, A; Mufti, G; List, A; Hall, J; Padron, E

Sallman, D A; Komrokji, R; Vaupel, C; Cluzeau, T; Geyer, S M; McGraw, K L; Al Ali, N H; Lancet, J; McGinniss, M J; Nahas, S; Smith, A E; Kulasekararaj, A; Mufti, G; List, A; Hall, J; Padron, E.

Affiliation

Sallman DA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Komrokji R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Vaupel C; Genoptix, Inc., a Novartis company, Carlsbad, CA, USA.
Cluzeau T; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Geyer SM; Hematology Department, CHU of Nice, Nice, France.
McGraw KL; Faculty of Medicine, University Nice Sophia Antipolis, Nice, France.
Al Ali NH; Mediterranean Center of Molecular Medicine, INSERM U1065, Nice, France.
Lancet J; French Group of Myelodysplasia, Paris, France.
McGinniss MJ; Health Informatics Institute, University of South Florida, Tampa, FL, USA.
Nahas S; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Smith AE; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Kulasekararaj A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Mufti G; Genoptix, Inc., a Novartis company, Carlsbad, CA, USA.
List A; Genoptix, Inc., a Novartis company, Carlsbad, CA, USA.
Hall J; King's College London School of Medicine, Department of Haematological Medicine, Rayne Institute, King's College London School of Medicine, London, UK.
Padron E; King's College London School of Medicine, Department of Haematological Medicine, Rayne Institute, King's College London School of Medicine, London, UK.

Leukemia ; 30(3): 666-73, 2016 Mar.

Article de En | MEDLINE | ID: mdl-26514544

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Phénotype / Syndromes myélodysplasiques / Leucémie aigüe myéloïde / Protéine p53 suppresseur de tumeur / Fréquence d'allèle / Mutation Type d'étude: Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Leukemia Sujet du journal: HEMATOLOGIA / NEOPLASIAS Année: 2016 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google